Your SlideShare is downloading. ×
Domperidone critique for position statement
Domperidone critique for position statement
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Domperidone critique for position statement

269

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
269
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  1. International Breastfeeding CentreThe recent Health Canada-endorsed warning about the use of domperidone was based on twostudies published in 20101,2. The information in these studies was taken from databases (one inthe Netherlands2 and one in Saskatchewan1) and did not demonstrate that domperidone causedany adverse health effects.The warning was based on information gathered from an entirely different population than thosewho would be taking domperidone for breastfeeding purposes and is thus not generalizable to thelactating population. The average age of the patients in the studies was 72.5 years in one2 and79.4 years in the other1. Many of the patients in the studies had pre-existing health problemssuch as high blood pressure, coronary artery disease, and congestive heart failure.There were, however, some notable trends that, when extrapolated to the breastfeedingpopulation largely comprised of younger, healthier women, are quite reassuring. In one study1,the authors concluded that the risk of a cardiac problem related to taking domperidone inyounger patients was much lower than in older patients. In fact, the risk quoted in youngerpatients was almost the same as that outcome occurring by chance alone (OR of 1.1 in thoseyounger than age 60 compared with an OR of 1.64 in those older than age 60). That study alsospecifies that the risk in females was significantly lower than in males (OR of 1.25 in femalescompared with an OR of 2.23 in males). It is also important to highlight that the risk decreasedthe longer the patient had been on domperidone1 which is important to note because motherstaking domperidone for the purposes of breastfeeding are often on it for many months.The warning regarding the use of domperidone in higher doses (>30mg per day) was based ononly one of the two studies2; the other study1 did not include any information about dosing. Inthe one study where dosing information was included, out of the 1304 deaths that were studied,only 10 patients were taking domperidone at the time of death. Of those 10 taking domperidone,only FOUR patients were documented to be taking higher doses of domperidone (>30mg perday). Thus this Health Canada-endorsed dose-related warning came from dosing datacompiled from a total of FOUR patients. In fact, the authors were not specifically cautioningphysicians not to prescribe higher doses, but rather were suggesting that “it is important to avoidprescribing domperidone to patients with a high risk of sudden cardiac death”. It is very hard tomake a case for a drastic reduction in domperidone dose in lactating women (wherein a dose of<30mg per day is not thought to be effective) when the data relied upon to generate the dosingwarning was based on such a small number of cases that do not at all demographically resemblethe population in which it is being prescribed.Domperidone is generally used to treat gastro-intestinal problems such as acid reflux. Some ofthe symptoms of heart disease may mimic symptoms of a gastro-intestinal illness. It is possiblethat some patients were taking domperidone for what was thought to be a gastro-intestinalproblem when, in fact, the symptoms may have been related to a heart problem. While theauthors attempted to account for this possible protopathic bias2, it is hard to tease out the etiologyof the potentially overlapping symptomatology, thus potentially affecting the results.Furthermore, because domperidone is available over-the-counter in parts of Europe, it isconceivable that the number of people self-medicating with domperidone is higher than the rate 1255 Sheppard Avenue East • Toronto, ON Canada • M2K 1E2 www.nbci.ca • clinic@nbci.ca Phone: 416-498-0002 fax : 416-498-0012
  2. International Breastfeeding Centreactually quoted in the Dutch study (as the study only took into account prescriptions fordomperidone2 and not over-the-counter use). This important fact may have skewed the results.Some other important limitations of the studies include the fact that key pieces of information areunavailable including smoking status, use of other non-prescription drugs, all of which can beimportant factors1 in affecting the study results.In summary, breastfeeding mothers using domperidone are generally younger, healthy females.They do not fall into the same demographics as the patients involved in the studies from whichthe warning was generated. Furthermore, with caution about the use of higher doses ofdomperidone stemming from a study where so few patients were actually on those higher doses,the Health Canada-endorsed warning regarding the use of domperidone in higher doses seems tobe an over-reaction. Finally, taking into account the other drawbacks of these studies as outlinedabove, there is no evidence that domperidone actually causes ventricular arrhythmias or suddencardiac death.1 Johannes CB et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohortof users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010 Sep;19(9): 881-888.2 van Noord C et al. Domperidone and ventricular arrhythmia or sudden cardiac death: apopulation-based case-control study in the Netherlands. Drug Saf. 2010 Nov 1; 33(11): 1003-1014. 1255 Sheppard Avenue East • Toronto, ON Canada • M2K 1E2 www.nbci.ca • clinic@nbci.ca Phone: 416-498-0002 fax : 416-498-0012

×